Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety.
- 1Department of Anesthesiology, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, People's Republic of China.
Abstract
Pain, depressive symptoms, and sleep disruption frequently overlap during the peripartum period, although their relationships are associative rather than established as causal. Esketamine, an N-methyl-D-aspartate receptor antagonist, has attracted interest as a peripartum intervention with potential effects on pain, mood, and sleep. This narrative review evaluates the clinical and mechanistic evidence for peripartum esketamine in analgesia, postpartum depressive symptoms, sleep-related outcomes, and maternal-infant safety, with particular attention to the directness and interpretability of the evidence. Most direct clinical evidence derives from cesarean-delivery studies, many of which are single-center trials. Evidence is most consistent for short-term analgesic benefit, whereas opioid-sparing effects are less consistent across individual studies and evidence syntheses. Several randomized trials suggest that low-dose peri-delivery esketamine may reduce early EPDS-defined screen-positive postpartum depressive symptoms, while evidence based on structured diagnostic outcomes remains limited. Evidence for sleep-related benefit remains preliminary and relies predominantly on subjective measures, with no direct postpartum polysomnographic evidence. Studied low-dose regimens have generally shown acceptable short-term maternal and neonatal tolerability in selected populations, but pregnancy-specific pharmacokinetics, lactation, and long-term offspring neurodevelopment remain insufficiently characterized. Overall, esketamine may represent an individualized adjunct in peripartum care, but current evidence does not support its routine prophylactic use. Future multicenter studies should incorporate diagnostic mood outcomes, objective sleep assessment, standardized treatment protocols, and long-term maternal and infant follow-up.
Related
- Bilateral postpartum renal cortical necrosis complicated by peripartum cardiomyopathy after postpartum hemorrhage: a case report
- Clinical Effects of Low-Dose Esketamine During Emergency Conversion From Labor Epidural Analgesia to Category I Cesarean Section: A Randomized Controlled Trial of Maternal Hemodynamics, Analgesia, Sedation, and Neonatal Outcomes
- Effects of different doses of esketamine as an adjunct to sufentanil-based patient-controlled intravenous analgesia on postoperative analgesia and opioid consumption following lumbar decompression surgery: a dose-finding randomized controlled trial
- Effect of Adding Esketamine to Patient-Controlled Intravenous Analgesia on Rebound Pain After Interscalene Brachial Plexus Block: A Randomized Controlled Trial
- Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review
BibTeX
@article{zhong2026peripartum,
title = {{Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety.}},
author = {Zhaoying Zhong and Baozhen Liao and Donglan Peng and Xiaohui Cao and Jianqiang Zeng},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s646618},
url = {https://europepmc.org/article/MED/42910224},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety.
AU - Zhaoying Zhong
AU - Baozhen Liao
AU - Donglan Peng
AU - Xiaohui Cao
AU - Jianqiang Zeng
PY - 2026
DA - 2026/10/17
JO - Drug design, development and therapy
DO - 10.2147/dddt.s646618
UR - https://europepmc.org/article/MED/42910224
AB - Pain, depressive symptoms, and sleep disruption frequently overlap during the peripartum period, although their relationships are associative rather than established as causal. Esketamine, an N-methyl-D-aspartate receptor antagonist, has attracted interest as a peripartum intervention with potential effects on pain, mood, and sleep. This narrative review evaluates the clinical and mechanistic evidence for peripartum esketamine in analgesia, postpartum depressive symptoms, sleep-related outcomes, and maternal-infant safety, with particular attention to the directness and interpretability of the evidence. Most direct clinical evidence derives from cesarean-delivery studies, many of which are single-center trials. Evidence is most consistent for short-term analgesic benefit, whereas opioid-sparing effects are less consistent across individual studies and evidence syntheses. Several randomized trials suggest that low-dose peri-delivery esketamine may reduce early EPDS-defined screen-positive postpartum depressive symptoms, while evidence based on structured diagnostic outcomes remains limited. Evidence for sleep-related benefit remains preliminary and relies predominantly on subjective measures, with no direct postpartum polysomnographic evidence. Studied low-dose regimens have generally shown acceptable short-term maternal and neonatal tolerability in selected populations, but pregnancy-specific pharmacokinetics, lactation, and long-term offspring neurodevelopment remain insufficiently characterized. Overall, esketamine may represent an individualized adjunct in peripartum care, but current evidence does not support its routine prophylactic use. Future multicenter studies should incorporate diagnostic mood outcomes, objective sleep assessment, standardized treatment protocols, and long-term maternal and infant follow-up.
SN - 1177-8881
ER -